---
layout: default
title: Iron
parent: Model Prediction Only (L5)
nav_order: 492
evidence_level: L5
indication_count: 6
---

# Iron
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **6** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Iron: From Iron Replacement to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia

## One-Sentence Summary

Iron is marketed in Canada under 12 licences, including several intravenous iron products. The TxGNN model predicts it may be effective for **vitamin B12- and folate-independent constitutional megaloblastic anemia**, but there are **0 clinical trials** and **0 publications** supporting this specific prediction. It is a model prediction only.

---

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Vitamin B12- and folate-independent constitutional megaloblastic anemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 12 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Iron is needed for hemoglobin synthesis and for enzymes involved in DNA synthesis, which explains why a model would link it to anemia-related diseases.

That link is weak here. This condition is defined by a megaloblastic defect that is independent of vitamin B12 and folate, and the supplied data show no pathway by which iron would correct it. The high score most likely reflects generic proximity to other anemia conditions in the knowledge graph, not a real therapeutic connection.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

The pack lists 12 licences in total; the 5 main ones are shown below. Dosage form and approved indication text were not provided.

| DIN | Product Name |
|---------|------|
| 2502917 | PMS-IRON SUCROSE |
| 2243716 | VENOFER |
| 2546078 | FERINJECT |
| 2471574 | VELPHORO |
| 2477777 | MONOFERRIC |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on a model score alone. There are no trials or publications for this disease, and no plausible mechanism links iron to correcting a B12/folate-independent megaloblastic defect.

Among the other predictions in the pack, **Plummer-Vinson syndrome** (score 99.89%) is far better supported. It has 19 publications, mostly reviews and case reports, describing iron repletion as first-line treatment. It is rated L4 with a "Proceed with Guardrails" recommendation, and it merits its own evaluation. The remaining predictions (non-syndromic esophageal malformation, biotin metabolic disease, vitamin deficiency disorder, esophageal disease) are also weak or indirect.

**To proceed, the following is needed:**
- Mechanism of action data (MOA) from DrugBank
- Health Canada package insert warnings and contraindications
- Original approved indication text for the Canadian licences
- Any biological or clinical evidence linking iron to this specific anemia subtype; without it, this indication should not advance
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

